Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease

Acta Neurologica Scandinavica

Volumn 109, Issue 1, 2004, Pages 45-51

  Korchounov, A ^a   Kessler, K R ^a   Schipper, H I ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Schlossberg Clin Parkinson's D   (Germany)

Author keywords

Adverse effects; Autonomic nervous system; Combination; Drug therapy; Orthostatic hypotension; Parkinson's disease

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; ROPINIROLE; SELEGILINE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR REFLEX; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; ELECTROCARDIOGRAM; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AGED; ANTIPARKINSON AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; INCIDENCE; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0742304141     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00172.x     Document Type: Article

References (37)

1. PIHA SJ, RINNE JO, RINNE UK, SEPPANEN A. Autonomic dysfunction in recent onset and advanced Parkinson's disease. Clin Neurol Neurosurg 1988;90:221-6.
2. GOETZ CG, LUTGE W, TANNER CM. Autonomic dysfunction in Parkinson's disease. Neurology 1986;36:73-5.
3. SÉNARD J, RAI S, LAPEYRE-MAESTRE M et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-9.
4. GOLDSTEIN DS, HOLMES C, CANNON III RO, EISENHOFER G, KOPIN IJ. Sympathetic cardioneuropathy in dysautonomias. New Engl J Med 1997;336:696-702.
5. WAKABAYASHI W, TAKAHASHI H, OHAMA E, SHIGEKI T, FUSAHIRO I. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993;60:609-12.
6. CALNE DB, BRENNAN J, SPIERS ASD, STERN GM. Hypotension caused by L-Dopa. BMJ 1970;151:470-4.
7. SACHS C, BERGLUND B, KAIJSER L. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopadecarboxylase inhibition. Acta Neurol Scand 1985;71: 37-42.
8. MONTASTRUC JL, CHAMONTIN B, RASCOL A. Parkinson's disease and hypertension: chronic bromocriptine treatment. Neurology 1985;35:1644-7.
9. QUINN NP, ILLAS A, LHERMITTE F, AGID Y. Bromocriptine in Parkinson's disease: a study of cardiovascular side effects. J Neurol Neurosurg Psychiatry 1981;44:426-9.
10. HAAPANIEMI TH, KALLIO MA, KORPELAINEN JT et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol 2000;415:868-74.
11. TURKKA J, SUOMINEN K, TOLONEN U, SOTANIEMI K, MYLLYLÄ VV. Selegiline diminishes cardiovascular autonomic response in Parkinson's disease. Neurology 1997;48:662-7.
12. DANIEL SE, LEES AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 1993; Suppl. 39;165-72.
13. HOEHN MM, YAHR MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
14. FAHN S, ELTON RL and the members of the UPDRS development committee. UPDRS: Unified Parkinson's Disease Rating Scale. In: FAHN S, MARSDEN CD, GOLDSTEIN M et al. eds. Recent developments in Parkinson's disease II. New York: Macmillan, 1987;153-64.
15. BRAUNE HJ, GIESENDOERFER U. Measurement of heart rate variations: influencing factors, normal values and diagnostic impact on diabetic autonomic neuropathy. Diabetes Res Clin Pract 1995;29:179-87.
16. KENNEDY WR, NAVARRO X, SUTHERLAND DVR. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995;45:773-80.
17. MALIK M, FARRELL T, CAMM AJ. Circadian rhythm of heart rate variability after acute myocardial infarction and its influence on the prognostic value of heart rate variability. Am J Cardiol 1990;66:1049-54.
18. LEWITT PA, WARD CD, LARSEN TA et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-14.
19. TANNER CM, GOETZ CG, GLANTZ RH, GLATT SL, KLAWANS HL. Pergolide mesylate and idiopathic Parkinson's disease. Neurology 1982;32:1175-9.
20. MEHTA AA, TOLIS G. Pharmacology of bromocriptine in health and disease. Drugs 1979;17:313-25.
21. BIANCHINE JR. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: GILMAN A, GOODMAN LS, RALL TW, MUROD F, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 7th edn. New York: Macmillan, 1985;473-90.
22. LIU W, VARNER KJ. Characterization of the sympathetic nerve responses to amphetamine: role of central alpha 2-adrenergic receptors. J Cardiovasc Pharmacol 1996;28: 712-22.
23. MANNELLI M, LAZZERI C, IANNI L et al. Dopamine and sympathoadrenal activity in man. Clin Exp Hypertens 1997;19:163-79.
24. EDEN RJ, WALLDUCK MS, PATEL B, OWEN DA. Autonomic and hemodynamic responses to SK&F101468 (ropinirole). a DA2 agonist, in anesthetised cats. Eur J Pharmacol 1990;175:333-40.
25. DE MAY C, ENTERLING D, MEINEKE I, YEULET S. Interactions between domperidone and ropinirole, a novel dopamine D2-receptor-agonist. Br J Clin Pharmacol 1991;32:483-8.
26. CHURCHYARD A, MATHIAS CJ, BOONKONGCHUEN P, LEES AJ. Autonomic effects of selegiline: possible cardiovascular toxicity on Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:228-34.
27. KUJAWA K. LEURGANS S, RAMAN R, BLASUCCI L, GOETZ CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57:1461-3.
28. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinon's disease. New Engl J Med 1993;328:176-84.
29. HEINONEN EH, SAVIJÄRVI M, KOTILA M, HAJBA A, SCHEININ M. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabo-lites in CSF. J Neural Transm 1993;5:193-202.
30. MASCHER HJ, KIKUTA C, MILLENDORFER A, SCHIEL H, LUDWIG G. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharmacol Ther 1997;35:9-13.
31. WHEELER T, WATKINS PY. Cardiac denervation in diabetes. BMJ 1973;4:584-6.
32. MECO G, PRATESI L, BONIFATI V. Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease. J Neurol 1991;238:195-9.
33. ORLAND HJ. Case report: ventricular arrhythmias with L-dopa and amantadine hydrochloride therapy during halothane anaesthesia. Anaesth Intensive Care 1974;2: 185-6.
34. PIMENTEL L, HUGHES B. Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. Pediatr Emerg Care 1991;7:89-92.
35. SARTORI M, PRATT CM, YOUNG JB. Torsade de Pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 1984;77:388-91.
36. VAN ACKERN K, DEUSTER JE, MAST GJ, SCHMIER J. Amantadin auf Herz und Kreislauf. Arzneimittelforschung 1975; 25:891-6.
37. SYVALAHTI EK, KUNELIUS R, LAUREN L. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol 1988;62:90-4.